S7028 revises Florida’s cancer research and treatment funding framework, primarily by amending the Casey DeSantis Cancer Research Program and the Cancer Innovation Fund. The bill updates definitions for “cancer center” and “Florida-based,” formally defines the Cancer Connect Collaborative, and revises the collaborative’s membership, duties, and reporting requirements. It directs the collaborative to review all Cancer Innovation Fund applications, prioritize proposals that expand cancer screening and treatment in underserved areas, and work with peer review panels that score applications based on scientific merit.
The bill also creates a new Cancer Connect Collaborative Research Incubator within the Department of Health, overseen by the collaborative, to fund a targeted area of cancer research over a five-year period. For the first five-year cycle beginning July 1, 2025, the targeted area is pediatric cancer. The incubator is designed to support peer-reviewed, competitive grants, with priority for projects that increase clinical trial participation, improve education and awareness, and strengthen collaboration between academic cancer centers and community oncologists. The bill further establishes the Bascom Palmer Eye Institute VisionGen Initiative within the William G. Bill Bankhead, Jr., and David Coley Cancer Research Program to support genetic and epigenetic research on inherited eye diseases and ocular oncology.
In practical terms, the bill expands and formalizes state oversight of cancer-related grantmaking, adds eligibility criteria for grant recipients, and imposes stronger conflict-of-interest, auditing, and reporting requirements. It requires annual reports on grant performance, outcomes, and best practices, and it adds detailed allocation-agreement requirements such as line-item budgets, quarterly expenditure reporting, and a cap on administrative expenses. It also makes participating cancer centers subject to annual reporting obligations tied to cancer mortality, external research funding, and case mix data.
The general sentiment reflected in the vote history is strongly supportive: the bill passed the Senate Health Policy Committee unanimously, then the Senate Appropriations Committee unanimously, and later passed the Senate floor 37-0. The absence of recorded opposition suggests broad agreement with the bill’s goals of expanding cancer research capacity, improving accountability, and directing resources toward underserved populations and pediatric cancer.
Notable points of contention are limited in the available record, but the bill’s structure suggests potential policy sensitivities around how grant priorities are set, which institutions qualify for funding, and how much discretion the collaborative and peer review panels have in recommending awards. The bill also centralizes significant authority in the Department of Health and the collaborative while requiring strict conflict-of-interest controls, indicating an emphasis on transparency and fairness in response to the competitive nature of the grants.
The bill amends sections 381.915 and 381.922, Florida Statutes, to expand and refine the state’s cancer research grant programs. It changes statutory definitions, revises the composition and duties of the Cancer Connect Collaborative, adds new eligibility and review standards for Cancer Innovation Fund grants, and creates a new five-year Cancer Connect Collaborative Research Incubator focused initially on pediatric cancer. It also establishes the Bascom Palmer Eye Institute VisionGen Initiative within the Bankhead-Coley cancer research program. These changes affect the Department of Health, the collaborative, participating cancer centers, hospitals, research institutions, and other eligible applicants for state cancer research funding.
The bill appears to have been received very positively in the Senate. It passed the Senate Health Policy Committee 10-0, the Senate Appropriations Committee 18-0, and the Senate floor 37-0, indicating unanimous support at each recorded stage. The bill’s emphasis on cancer research, underserved communities, pediatric cancer, and accountability measures likely contributed to the broad consensus.
No formal opposition is reflected in the available committee or floor votes, but the bill does contain several areas that could draw policy debate. These include the prioritization of certain applicants and geographic areas, the requirement that peer review panels score proposals and that the collaborative use those scores in funding recommendations, and the eligibility rules that favor particular types of hospitals, clinics, and research entities. Another possible point of discussion is the creation of a targeted research incubator with a specific first focus on pediatric cancer, which may raise questions about future target areas, funding allocation, and whether the state should concentrate resources in selected research domains versus broader cancer research efforts.